NTC Acquires Pharmathen's Ophthalmology Business

NTC S.r.l., an Italian pharmaceutical company, has completed the acquisition of Pharmathen's ophthalmology business. This deal, supported by Wise Equity, expands NTC's offerings in the glaucoma segment, reinforcing its position in the European eye care market.

The acquisition allows NTC to achieve around €100 million in revenues, with over 80% coming from ophthalmology. It also expands NTC's reach into the U.S. market. CEO Riccardo Carbucicchio emphasized the strategic fit with NTC’s portfolio, highlighting the company's commitment to providing effective glaucoma treatments.

The integration promises commercial synergies and opens opportunities for international expansion. With an already robust pipeline addressing clinical needs, NTC further solidifies its status as a leading player in European ophthalmology.